Medline financials
$34.98−0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $28.43B |
| Gross profit | $7.52B |
| Gross margin | 26.4% |
| Operating income | $2.29B |
| Net income | $1.16B |
| Net margin | 4.1% |
| Diluted EPS | $1.43 |
| EBITDA | $3.30B |
| Operating cash flow | $1.74B |
| Free cash flow | $1.30B |
| Diluted shares | 809.7M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $1.94B |
| Short-term investments | $0.00 |
| Total debt | $12.56B |
| Total assets | $38.48B |
| Total liabilities | $19.20B |
| Shareholders' equity | $19.29B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology